Latest / DDReg Knowledge Capsule / Global Biosimilar Pathways 2026 : US, EU, UK & Asia

Transcript

Global Biosimilar Pathways 2026 : US, EU, UK & Asia · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to Deidre Reg Knowledge Capsule. So I want you
• 0:03
  Speaker 1: to imagine spending, I don't know, over $ 100 million to
• 0:06
  Speaker 1: prove a biosimilar drug is just perfectly safe and highly effective.
• 0:11
  Speaker 1: And you're doing this in a state-of-the-art lab.
• 0:12
  Speaker 2: Right, and the data is completely flawless.
• 0:15
  Speaker 1: Exactly, flawless data. So you submit your application to regulators
• 0:19
  Speaker 1: in London, fully expecting an approval, only to have the
• 0:22
  Speaker 1: entire package just thrown out.
• 0:24
  Speaker 2: Oh, yeah, completely rejected.
• 0:25
  Speaker 1: Right, and why? Because somewhere along the line, Your team
• 0:29
  Speaker 1: filled out the legal paperwork using a reference product designated
• 0:32
  Speaker 1: for New York. And, you know, you failed to build
• 0:35
  Speaker 1: the proper scientific bridge between the two.
• 0:37
  Speaker 2: It is a staggering scenario, honestly. But it actually happens.
• 0:41
  Speaker 2: We are looking at the 2026 global biosimilar regulatory landscape today,
• 0:45
  Speaker 2: a space where, well, this core paradox is just glaringly obvious.
• 0:50
  Speaker 1: Yeah, that tension between the science and the law.
• 0:52
  Speaker 2: Exactly, because the actual science of biosimilarity, you know, the chemistry,
• 0:56
  Speaker 2: the biology, it's becoming incredibly harmonized worldwide. Regulators on completely
• 1:01
  Speaker 2: different continents are looking at the exact same fundamental biological truths.
• 1:05
  Speaker 1: But the legal and procedural realities are still strictly territorial.
• 1:09
  Speaker 2: Very much so. They are fragmented, deeply entrenched, and quite frankly,
• 1:13
  Speaker 2: highly unforgiving.
• 1:15
  Speaker 1: Which is why today's Deep Dives is so crucial. We
• 1:18
  Speaker 1: are unpacking a comprehensive 2026 industry briefing On this exact
• 1:23
  Speaker 1: global strategy. We're covering the heavyweight agencies, so the FDA
• 1:27
  Speaker 1: in the U.S., the EMA in Europe, the MHRE in
• 1:30
  Speaker 1: the U.K., the NMPA and CDE in China, and of
• 1:33
  Speaker 1: course the PMDA in Japan.
• 1:35
  Speaker 2: Right, the big five.
• 1:35
  Speaker 1: Yeah. And since you listening already follow the pharmaceutical space,
• 1:39
  Speaker 1: you know, we aren't talking about generic aspirin here. We're
• 1:41
  Speaker 1: dealing with massive, complex therapeutic proteins grown in living cells.
• 1:46
  Speaker 2: Definitely not a simple chemical copy.
• 1:48
  Speaker 1: No, not at all. So looking at this 2026 landscape,
• 1:51
  Speaker 1: how are these different agencies actually defining high similarity today?
• 1:55
  Speaker 1: Because the scientific goal seems universal, but the regulatory goalposts
• 1:59
  Speaker 1: just constantly shift depending on the region.
• 2:01
  Speaker 2: Well, the foundational scientific objective is genuinely shared across the board.
• 2:05
  Speaker 2: You have to demonstrate that your proposed biosimilar is highly
• 2:08
  Speaker 2: similar to an established reference biologic.
• 2:10
  Speaker 1: Meaning the original branded drug. Right.
• 2:13
  Speaker 2: And you have to show that any minor biological variations...
• 2:17
  Speaker 2: like slight differences in glycosylation patterns or how the protein folds,
• 2:21
  Speaker 2: that those don't translate into clinically meaningful differences in safety, purity, potency,
• 2:27
  Speaker 2: or efficacy.
• 2:28
  Speaker 1: Because you literally cannot make an exact molecular clone using
• 2:31
  Speaker 1: living cell lines. Exactly.
• 2:33
  Speaker 2: It's impossible. So the burden of proof is entirely on
• 2:36
  Speaker 2: showing those tiny, inevitable variances just do not matter to
• 2:39
  Speaker 2: the human immune system.
• 2:41
  Speaker 1: But how these different agencies actually demand proof of that similarity...
• 2:45
  Speaker 1: I mean, that's where the ideological fragmentation really happens. We
• 2:47
  Speaker 1: see very distinct regulatory philosophies. Oh, absolutely. Like in the U.S.,
• 2:52
  Speaker 1: the FDA leans really heavily into this totality of the
• 2:55
  Speaker 1: evidence approach. They're willing to accept high similarity despite minor
• 2:59
  Speaker 1: structural differences, provided the cumulative weight of all the data, analytical, non-clinical, clinical,
• 3:05
  Speaker 1: paints a reassuring picture.
• 3:06
  Speaker 2: Yeah, but you contrast that directly with the European Union
• 3:08
  Speaker 2: and the U.K. The EMA and MHRA, they do not
• 3:11
  Speaker 2: just look at a giant pile of evidence all at once.
• 3:14
  Speaker 2: They require a very rigid, stepwise comparability exercise.
• 3:19
  Speaker 1: So it's much more sequential.
• 3:20
  Speaker 2: Highly sequential. You start with this exhaustive initial quality comparison
• 3:25
  Speaker 2: in the lab. And the results of that specific first
• 3:28
  Speaker 2: step dictate precisely what non-clinical and clinical studies you are
• 3:33
  Speaker 2: even permitted or required to do next.
• 3:36
  Speaker 1: And Japan's PMDA operates on a similar track, don't they?
• 3:39
  Speaker 1: Very quality-led.
• 3:40
  Speaker 2: Yeah, they evaluate the critical quality attributes first, and then
• 3:43
  Speaker 2: they tailor the subsequent evidence based on the exact degree
• 3:46
  Speaker 2: of similarity you showed in that initial lab data.
• 3:49
  Speaker 1: Right. And then there's China's CDE, which takes this much
• 3:52
  Speaker 1: more holistic, evidence-heavy, stepwise approach. They really want to see pharmaceutical, non-clinical,
• 3:58
  Speaker 1: and clinical similarity fully established before they'll even entertain concepts
• 4:03
  Speaker 1: like indication extrapolation.
• 4:05
  Speaker 2: Which, just for context, is when a biosimilar gets approved
• 4:07
  Speaker 2: for all the diseases the original drug treats, even if
• 4:10
  Speaker 2: it was only formally tested for one. China is very
• 4:13
  Speaker 2: cautious about that.
• 4:14
  Speaker 1: It makes me think of traveling globally with a high-end hairdryer.
• 4:17
  Speaker 2: A hairdryer. Okay, I like it.
• 4:18
  Speaker 1: Right, so the electricity, the core science of how the
• 4:21
  Speaker 1: heating element and the fan work, that's identical everywhere in
• 4:24
  Speaker 1: the world. But if you do not have the exact
• 4:28
  Speaker 1: country-specific adapter, in this case the legally accepted local reference product...
• 4:33
  Speaker 1: You're going to blow a fuse.
• 4:34
  Speaker 2: That's actually a perfect analogy.
• 4:36
  Speaker 1: Yeah. You simply cannot plug a device configured for the U.S.
• 4:40
  Speaker 1: straight into a U.K. regulatory wall and expect it to function.
• 4:43
  Speaker 1: It doesn't matter how perfect the internal mechanics are.
• 4:45
  Speaker 2: No, it doesn't. Because of those different legal adapters, a
• 4:48
  Speaker 2: global development program can basically never rely on a single
• 4:52
  Speaker 2: universally accepted dossier. A sponsor has to account for local,
• 4:57
  Speaker 2: legally acceptable reference products in every single target market.
• 5:01
  Speaker 1: Which sounds incredibly expensive.
• 5:02
  Speaker 2: Oh, it is. They have to figure out the complex
• 5:05
  Speaker 2: bridging evidence required if they test against a foreign version
• 5:08
  Speaker 2: of the drug. And they have to navigate these incredibly
• 5:11
  Speaker 2: specific market dependent post-approval requirements.
• 5:15
  Speaker 1: Which leads us to the biggest earthquake in this field
• 5:18
  Speaker 1: right now. And this is huge for the 2026 landscape.
• 5:22
  Speaker 1: We are seeing a massive paradigm shift phasing out routine testing.
• 5:26
  Speaker 1: Comparative efficacy studies or CES.
• 5:29
  Speaker 2: Yes. The end of the routine phase three efficacy trial. Right.
• 5:32
  Speaker 1: Because for years, the absolute gold standard for proving a
• 5:35
  Speaker 1: biosimilar worked was running these massive, wildly expensive efficacy trials
• 5:40
  Speaker 1: on thousands of human patients. Now, regulators are increasingly willing
• 5:44
  Speaker 1: to waive those human trials entirely.
• 5:47
  Speaker 2: And the causality behind this shift is entirely driven by
• 5:50
  Speaker 2: just spectacular loops in analytical laboratory technology.
• 5:53
  Speaker 1: Like the equipment is just that much better now.
• 5:55
  Speaker 2: Exactly. Historically, regulators demanded those human efficacy trials because the
• 6:00
  Speaker 2: lab equipment simply wasn't sensitive enough to spot microscopic differences in, say,
• 6:04
  Speaker 2: how a protein was folded or exactly how it bound
• 6:07
  Speaker 2: to a target receptor.
• 6:08
  Speaker 1: But today.
• 6:09
  Speaker 2: Today, we use advanced mass spectrometry, surface plasmon resonance, nuclear
• 6:13
  Speaker 2: magnetic resonance imaging. I mean, we can analyze these molecules
• 6:16
  Speaker 2: down to their atomic structures and map every single amino
• 6:19
  Speaker 2: acid interaction. Wow.
• 6:21
  Speaker 1: So regulators have basically realized that if a sponsor's analytical
• 6:25
  Speaker 1: data is flawless at an atomic level, putting thousands of
• 6:28
  Speaker 1: patients through an efficacy trial doesn't actually tell us anything new.
• 6:32
  Speaker 2: Right. It just confirms what the high-performance liquid chromatography already
• 6:36
  Speaker 2: proved in the lab weeks ago.
• 6:38
  Speaker 1: That is wild. And the timeline of this regulatory acceptance
• 6:42
  Speaker 1: has been staggering. The UK's MHRA moved earliest and most aggressively,
• 6:47
  Speaker 1: stating a CES is already considered unnecessary in most cases,
• 6:51
  Speaker 1: if scientifically justified.
• 6:53
  Speaker 2: And Japan followed suit pretty closely. The PMDA released a
• 6:56
  Speaker 2: major Q & A in May 2026, confirming that a
• 6:59
  Speaker 2: CDS might not be necessary... Backed by this early consideration document.
• 7:04
  Speaker 1: Basically challenging sponsors to prove when human studies actually add
• 7:07
  Speaker 1: any value.
• 7:08
  Speaker 2: Yes, they openly challenge it now.
• 7:09
  Speaker 1: But the U.S. and Europe are still kind of catching up,
• 7:12
  Speaker 1: and their timelines are what make this a very dangerous
• 7:14
  Speaker 1: game for sponsors. The FDA issued draft guidance back in
• 7:17
  Speaker 1: October 2025 stating that if analytical similarity, PK studies, you know,
• 7:22
  Speaker 1: pharmacokinetic studies and immunogenicity assessments are strong enough, the efficacy
• 7:26
  Speaker 1: study might be eliminated.
• 7:27
  Speaker 2: Might be. That's the key word. Right.
• 7:30
  Speaker 1: And the EMA published a final reflection paper in March
• 7:33
  Speaker 1: 2026 supporting a tailored approach without a CES for well-characterized products.
• 7:38
  Speaker 1: But they also entered a consultation for a concept paper
• 7:41
  Speaker 1: to revise their main overarching guideline in July 2026.
• 7:44
  Speaker 2: Yeah, it's a very fluid situation.
• 7:47
  Speaker 1: So, wait, let me push back here on behalf of
• 7:49
  Speaker 1: you listening. Because if I'm a pharmaceutical sponsor, look at
• 7:52
  Speaker 1: the terminology. The FBA guidance from late 2025 is still
• 7:56
  Speaker 1: just a draft guidance.
• 7:57
  Speaker 2: Right.
• 7:58
  Speaker 1: And the EMA overarching guideline is technically still under revision
• 8:01
  Speaker 1: as of mid-2026. So isn't it insanely risky to bet
• 8:06
  Speaker 1: a multi-million dollar development program on skipping clinical trials when
• 8:09
  Speaker 1: the overarching frameworks are literally still evolving?
• 8:12
  Speaker 2: It is the single biggest risk a developer can take today.
• 8:15
  Speaker 2: I mean, this shift is a complete strategic minefield. Agencies
• 8:18
  Speaker 2: expect sponsors to treat clinical studies as highly specific questions
• 8:21
  Speaker 2: to be answered, not traditional regulatory boxes to be checked.
• 8:25
  Speaker 1: So you really have to prove it.
• 8:26
  Speaker 2: Beyond a shadow of a doubt. You have to prove
• 8:28
  Speaker 2: that your analytical data resolves all residual uncertainty.
• 8:31
  Speaker 1: Meaning you aren't getting an automatic waiver. You're earning the
• 8:35
  Speaker 1: right to a tailored, reduced clinical program through flawless early science.
• 8:42
  Speaker 2: Exactly. If you try to skip the Phase 3 trial
• 8:45
  Speaker 2: just to save, I don't know, $ 70 million, but your
• 8:48
  Speaker 2: mass spectrometry data leaves even a sliver of scientific doubt
• 8:51
  Speaker 2: about how the molecule binds... your application will be rejected instantly.
• 8:55
  Speaker 1: Wow. And we can't forget China's NMPA in this global
• 9:00
  Speaker 1: equation either. They are still highly evidence dependent. Even with
• 9:04
  Speaker 1: advanced analytics, a sponsor absolutely cannot assume that just because
• 9:08
  Speaker 1: the FDA or EMA allowed them to reduce their clinical package,
• 9:11
  Speaker 1: China will automatically accept that same reduced data set.
• 9:14
  Speaker 2: Definitely not. So the burden of proof has effectively shifted
• 9:17
  Speaker 2: from the hospital clinic right back to the laboratory.
• 9:19
  Speaker 1: Which means if a sponsor is arguing to skip massive trials...
• 9:23
  Speaker 1: their foundational laboratory data must be absolute perfection.
• 9:26
  Speaker 2: Spot on.
• 9:27
  Speaker 1: And the single most critical decision for generating that perfect
• 9:30
  Speaker 1: lab data is determining what specific drug they're actually comparing
• 9:33
  Speaker 1: their biosimilar to.
• 9:35
  Speaker 2: Yeah, this brings us to the concept of the regulatory anchor.
• 9:38
  Speaker 2: This is the legal foundation of the entire global strategy.
• 9:41
  Speaker 2: Every biosimilar application must be legally anchored to an original
• 9:45
  Speaker 2: reference product that is approved in that specific target market.
• 9:49
  Speaker 1: And this is where using the wrong adapter, going back
• 9:51
  Speaker 1: to our hairdryer, will actually blow up a multi-million dollar program.
• 9:55
  Speaker 1: The U.S. FDA legally anchors a biosimilar application, specifically a
• 10:00
  Speaker 1: 351K application, to a U.S. licensed reference product.
• 10:04
  Speaker 2: The EU requires an EU or EEA authorized reference medicinal product. Right.
• 10:09
  Speaker 1: The U.K., operating under their January 2025 guidance, expects a U.K.
• 10:13
  Speaker 1: reference product. Japan expects a Japanese-approved biopharmaceutical. And China strongly
• 10:18
  Speaker 1: prefers originators already approved for import or clinical trials within China.
• 10:22
  Speaker 2: So consider the logistical nightmare for a global developer. Are
• 10:25
  Speaker 2: they realistically going to run five separate comparability trials, sourcing
• 10:29
  Speaker 2: five different regional versions of an incredibly expensive original biologic,
• 10:33
  Speaker 2: just to satisfy the letter of the law in each
• 10:35
  Speaker 2: local market?
• 10:37
  Speaker 1: I mean, the procurement costs alone would bankrupt the program,
• 10:39
  Speaker 1: not to mention the time delays.
• 10:41
  Speaker 2: Exactly. So the solution is building a scientific bridge. The
• 10:44
  Speaker 2: bridging strategy is how a developer avoids running all those
• 10:48
  Speaker 2: redundant trials.
• 10:49
  Speaker 1: OK. So if a developer uses a European reference product
• 10:52
  Speaker 1: for their primary clinical trials but wants to file in
• 10:55
  Speaker 1: the U.S., they have to scientifically prove that the European
• 10:59
  Speaker 1: reference product is analytically and pharmacokinetically identical to the U.S.
• 11:04
  Speaker 1: reference product. Right.
• 11:05
  Speaker 2: It's a three-way analytical comparison. You are proving that your
• 11:08
  Speaker 2: biosimilar equals the European reference. And the European reference equals
• 11:12
  Speaker 2: the U.S. reference, so therefore, logically, your biosimilar must equal
• 11:16
  Speaker 2: the U.S.
• 11:17
  Speaker 1: Reference. The transitive property of regulatory science. And regulators are
• 11:21
  Speaker 1: providing pathways for this, but the rules are incredibly strict.
• 11:24
  Speaker 1: The FDA's revised draft Q & As from March 2026
• 11:29
  Speaker 1: allow foreign comparator data under certain conditions without automatically forcing
• 11:33
  Speaker 1: a massive three-way human PK study.
• 11:36
  Speaker 2: But to get that allowance, the developer must adhere strictly
• 11:38
  Speaker 2: to the FDA's September 2025 analytical guidance. That dictates exactly
• 11:43
  Speaker 2: how this comparative bridging has to work at a molecular
• 11:46
  Speaker 2: level in the lab.
• 11:47
  Speaker 1: Japan is showing some flexibility here too, right?
• 11:49
  Speaker 2: They are. As of September 2025, the PMDA allows non-Japanese
• 11:54
  Speaker 2: clinical data, provided the sponsor can scientifically justify that ethnic factors,
• 11:59
  Speaker 2: like genetic differences in drug metabolism, do not materially affect
• 12:02
  Speaker 2: the comparability conclusion.
• 12:04
  Speaker 1: And China... predictably, requires very early planning regarding the origin
• 12:09
  Speaker 1: of the reference product. If a sponsor uses different origins,
• 12:12
  Speaker 1: they are locked into providing extensive, highly scrutinized comparability evidence.
• 12:17
  Speaker 2: Yeah. So let's walk through the ultimate nightmare scenario here.
• 12:20
  Speaker 1: Let's do it.
• 12:21
  Speaker 2: A sponsor decides to launch globally. They buy a massive
• 12:24
  Speaker 2: commercial batch of the European reference product to run their
• 12:27
  Speaker 2: primary tests, planning to file in the U.S.
• 12:30
  Speaker 1: Later.
• 12:31
  Speaker 2: But they don't set up the analytical bridge with the U.S.
• 12:34
  Speaker 2: reference product beforehand. They just assume the molecules are identical because, well,
• 12:37
  Speaker 2: they're made by the same original parent company. Oh, no.
• 12:40
  Speaker 1: So they just guess. Basically.
• 12:42
  Speaker 2: And that assumption is catastrophic. Comparator batches cannot be selected
• 12:46
  Speaker 2: market by market after the studies have started. Even if
• 12:49
  Speaker 2: the original parent company makes both the EU and U.S. versions,
• 12:53
  Speaker 2: they might be manufactured in different facilities using slightly different
• 12:56
  Speaker 2: cell lines or purification processes.
• 12:59
  Speaker 1: So if the scientific bridge is weak... meaning the developer
• 13:02
  Speaker 1: cannot prove the EU and U.S. reference products are identical,
• 13:06
  Speaker 1: what happens?
• 13:07
  Speaker 2: The FDA will throw out the foreign data. Full stop.
• 13:10
  Speaker 2: The developer will be forced to run additional redundant pharmacokinetic studies,
• 13:14
  Speaker 2: or worse, duplicate their entire multi-year clinical development program entirely
• 13:18
  Speaker 2: from scratch.
• 13:19
  Speaker 1: Just because of one mistake in sourcing the reference product
• 13:23
  Speaker 1: or misinterpreting a draft guidance on bridging, the entire global
• 13:26
  Speaker 1: launch derails.
• 13:27
  Speaker 2: Yes.
• 13:28
  Speaker 1: Since the stakes are phenomenally high. The briefing outlines a
• 13:31
  Speaker 1: specific playbook for developers navigating 2026. Six strategic decisions for
• 13:36
  Speaker 1: a global strategy.
• 13:37
  Speaker 2: And rather than a simple checklist, this playbook is really
• 13:40
  Speaker 2: broken down into strategic phases. The first phase is entirely
• 13:44
  Speaker 2: about sequencing and sourcing. So decision one, a developer must
• 13:48
  Speaker 2: define their target market sequence early.
• 13:50
  Speaker 1: Like, are they executing a first wave launch, hitting the US, EU, UK, China,
• 13:55
  Speaker 1: and Japan simultaneously? Or are they staggering the submissions, allowing
• 14:00
  Speaker 1: later markets to rely on evidence generated for the earlier filings.
• 14:03
  Speaker 2: Precisely. And once that sequence is locked, decision two is
• 14:06
  Speaker 2: they have to nail down the reference product strategy before
• 14:09
  Speaker 2: a single clinical trial begins. They have to map out
• 14:12
  Speaker 2: the legally relevant reference product for every target market, figure
• 14:16
  Speaker 2: out where they're sourcing the comparator batches, ensure they have
• 14:18
  Speaker 2: enough lots, and propose the analytical bridging strategy across every
• 14:22
  Speaker 2: single region. Right.
• 14:24
  Speaker 1: Which leads to decision three, hyperinvestment in the laboratory. The
• 14:28
  Speaker 1: entire global strategy now hinges on avoiding the massive comparative
• 14:31
  Speaker 1: efficacy study, so developers must invest heavily in analytical comparability
• 14:35
  Speaker 1: early on.
• 14:36
  Speaker 2: Because the better and more sensitive the lab data, the
• 14:39
  Speaker 2: stronger the argument for a tailored, reduced clinical program.
• 14:43
  Speaker 1: Exactly. That flows directly into decision four, treating clinical studies
• 14:48
  Speaker 1: as questions to resolve remaining uncertainty. If the mass spec
• 14:52
  Speaker 1: data already proved how the molecule binds... A developer needs
• 14:55
  Speaker 1: to ruthlessly challenge whether a human clinical study adds any
• 14:59
  Speaker 1: actual value to that specific question.
• 15:01
  Speaker 2: But crucially, and this is decision five, they must obtain
• 15:05
  Speaker 2: agency advice before reducing that clinical package.
• 15:09
  Speaker 1: No automatic waivers. None.
• 15:10
  Speaker 2: A sponsor cannot unilaterally decide to waive a trial just
• 15:14
  Speaker 2: based on reading a draft guidance. They have to go
• 15:16
  Speaker 2: to the FDA, the EMA, the PMDA, present their flawless
• 15:19
  Speaker 2: analytical data and and get explicit regulatory blessing on their
• 15:23
  Speaker 2: tailored approach before proceeding.
• 15:25
  Speaker 1: And the final piece, decision six, is maintaining a global
• 15:28
  Speaker 1: core dossier with controlled regional adaptations. A developer wants one unified,
• 15:33
  Speaker 1: highly defensible global scientific narrative. They do not want five
• 15:36
  Speaker 1: separate scientific stories.
• 15:38
  Speaker 2: But that core dossier still has to be carefully customized
• 15:41
  Speaker 2: to account for the local legal quirks and specific bridging
• 15:44
  Speaker 2: requirements of each region.
• 15:45
  Speaker 1: Essentially, this phased, highly surgical approach is the only way
• 15:49
  Speaker 1: to survive 2026. It's not about throwing money at the
• 15:53
  Speaker 1: largest possible clinical trial anymore. It's about generating the most
• 15:56
  Speaker 1: sensitive evidence possible and knowing exactly how to translate it
• 15:59
  Speaker 1: for each local regulator.
• 16:01
  Speaker 2: Yeah, it reduces unnecessary duplication, saves potentially hundreds of millions
• 16:06
  Speaker 2: in capital, and shaves years off the timeline. And most importantly,
• 16:10
  Speaker 2: it avoids the really dangerous trap of assuming false global harmonizations.
• 16:16
  Speaker 2: It forces developers to respect the reality that while the
• 16:19
  Speaker 2: science of the molecule is global, the law governing its
• 16:22
  Speaker 2: approval is fiercely local.
• 16:24
  Speaker 1: So to recap the landscape for you listening, executing a
• 16:26
  Speaker 1: successful global biosimilar rollout in 2026 requires this masterful balancing act.
• 16:32
  Speaker 1: Developers have to leverage harmonized global science using atomic-level analytical
• 16:36
  Speaker 1: testing while navigating heavily fragmented, highly territorial local laws.
• 16:41
  Speaker 2: Relying on rock-solid pre-planned analytical bridging to connect those different
• 16:45
  Speaker 2: regional reference products.
• 16:46
  Speaker 1: Exactly. And carefully tiptoeing through the massive phase-out of routine
• 16:52
  Speaker 1: efficacy trials, knowing that skipping a human trial is an
• 16:55
  Speaker 1: earned privilege based on flawless lab data, not an automatic
• 16:58
  Speaker 1: regulatory right.
• 17:00
  Speaker 2: Right. And all of this, it points toward a very
• 17:02
  Speaker 2: important horizon line that I want to bring up. We
• 17:04
  Speaker 2: know the International Council for Harmonization, the ICH, endorsed the
• 17:07
  Speaker 2: development of the M18 framework back in November 2025. The
• 17:11
  Speaker 2: ICH M18, right? Yeah. And the stated goal of M18
• 17:15
  Speaker 2: is to finally create consistent, unified, global principles for deciding
• 17:20
  Speaker 2: exactly when comparative efficacy studies are actually scientifically useful and
• 17:24
  Speaker 2: when they can be universally waived.
• 17:26
  Speaker 1: That's like the holy grail of global regulatory alignment. If
• 17:29
  Speaker 1: M18 works, the rules on clinical trials theoretically become the
• 17:32
  Speaker 1: same everywhere.
• 17:33
  Speaker 2: That is the goal. But as work on the ICH
• 17:36
  Speaker 2: M18 framework continues through 2026 and beyond, it raises a
• 17:40
  Speaker 2: really profound question for the industry. You have to ask yourself,
• 17:43
  Speaker 2: if M18 eventually succeeds in standardizing these clinical rules worldwide,
• 17:48
  Speaker 2: will the intense strategic advantage of navigating these fragmented regional
• 17:52
  Speaker 2: pathways disappear completely?
• 17:53
  Speaker 1: Oh, that's interesting.
• 17:54
  Speaker 2: Or will deeply entrenched local legal requirements, like the strict
• 17:59
  Speaker 2: demand for specific regional reference products, Will they always find
• 18:03
  Speaker 2: a way to trump global scientific consensus?
• 18:05
  Speaker 1: It is a phenomenal question to leave on. Will we
• 18:08
  Speaker 1: ever reach a point where a biosimilar developer doesn't need
• 18:10
  Speaker 1: to carry five different legal adapters? Or will the global
• 18:14
  Speaker 1: regulatory landscape always require them to painstakingly rewire the plug
• 18:19
  Speaker 1: just to get the scientific hairdryer to turn on in
• 18:21
  Speaker 1: a new country?
• 18:22
  Speaker 2: It's the ultimate tension between science and law.
• 18:24
  Speaker 1: It really is. And it's going to define the next
• 18:26
  Speaker 1: decade of biopharmaceuticals. Well, thank you for joining us on
• 18:30
  Speaker 1: this deep dive into the 2026 Global Biosimilar Regulatory Landscape.
• 18:35
  Speaker 1: Keep exploring these incredible nuances of global regulatory intelligence, because
• 18:39
  Speaker 1: as we've seen today, the difference between a global breakthrough
• 18:42
  Speaker 1: and a $ 100 million failure isn't just the science, it
• 18:45
  Speaker 1: is entirely in the strategy. Catch you next time.